Compared groups and clinical data | Group A | Group B | Statistical significance p |
---|---|---|---|
n = 54 | n = 11 | ||
n (%) | (%) | ||
Males/females | 20 (37.0%)/34 (63.0%) | 5 (45.5%)/6 (54.5) | NS |
Age (years) | 57.9 ± 11.0 | 46.1 ± 10.8 | p = 0.001 |
Ischemic heart disease | 18 (33.3%) | 2 (18.2%) | NS |
Myocardial infarct | 7 (13.0%) | 1 (9.1%) | NS |
Cardiac failure | 22 (40.7%) | 3 (27.3%) | NS |
IFG/IGT | 34 (63.0%) | 4 (36.4%) | NS |
CKD | 14 (25.9%) | 1 (9.1%) | NS |
Stroke | 3 (5.6%) | 0 | NS |
Cerebral arteries failure | 3 (5.6%) | 0 | NS |
Hyperuricemia | 24 (44.4%) | 2 (18.2%) | NS |
Dyslipidaemia | 52 (96.3%) | 9 (81.8%) | NS |
Tobacco smoking | 5 (9.3%) | 0 | NS |
ACEI | 44 (81.5%) | 1 (9.1%) | p < 0.0001 |
ARB | 17 (31.5%) | 0 | p = 0.05 |
Diuretics | 35 (64.8%) | 1 (9.1%) | p < 0.01 |
CCA | 19 (35.2%) | 0 | p < 0.05 |
BB | 23 (40.7%) | 2 (18.2%) | NS |
Spironolactone | 17 (31.5%) | 1 (9.1%) | NS |
ARA | 7 (13.0%) | 0 | NS |
ASA | 15 (27.8%) | 1 (9.1%) | NS |
Hypolipemic treatment a | 31 (57.4%) | 4 (36.4%) | NS |